Drugs that contain Dasatinib
1. Phyrago patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202778 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11324745 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
| US11298356 | NANOCOPOEIA | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(16 years from now) | |
Market Authorisation Date: 05 December, 2023
Treatment: Use of dasatinib for treatment of newly diagnosed adults with ph+ cml in chronic phase, when coadministered with a gastric acid reducing agent; Use of dasatinib for treatment of adults with ph+ all wi...
Dosage: TABLET;ORAL
More Information on Dosage
PHYRAGO family patents
2. Sprycel patents expiration
SPRYCEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6596746 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Jun, 2020
(3 years ago) | |
| US7491725 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Mar, 2026
(1 year, 10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125875 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(4 years ago) | |
| US7153856 | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Apr, 2020
(3 years ago) | |
|
US7125875 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(3 years ago) | |
|
US7153856 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Oct, 2020
(3 years ago) | |
|
US6596746 (Pediatric) | BRISTOL MYERS SQUIBB | Cyclic protein tyrosine kinase inhibitors |
Dec, 2020
(3 years ago) | |
| US8680103 | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Feb, 2025
(9 months from now) | |
|
US8680103 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Aug, 2025
(1 year, 3 months from now) | |
|
US7491725 (Pediatric) | BRISTOL MYERS SQUIBB | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Sep, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-225) | Dec 21, 2025 |
| Pediatric Exclusivity(PED) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-164) | Nov 09, 2024 |
| New Patient Population(NPP) | Nov 09, 2020 |
| New Indication(I-791) | Dec 21, 2021 |
| New Dosing Schedule(D-120) | May 21, 2012 |
| M(M-94) | Oct 28, 2013 |
| Orphan Drug Exclusivity(ODE) | Jun 28, 2013 |
Market Authorisation Date: 28 June, 2006
Treatment: A method for the treatment of cancer
Dosage: TABLET;ORAL
How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage
SPRYCEL family patents